Sellas Life Sciences Group Inc (SLS)

$1.71 0.00 (N/A)
Market Cap 170.62M
Revenue (ttm) 0.00
Net Income (ttm) -30.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,682,600
Avg Vol 2,033,530
Day's Range N/A - N/A
Shares Out 99.78M
Stochastic %K 11%
Beta 2.34
Analysts Strong Sell
Price Target $5.83

Latest News on SLS

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 20, 2025, 8:00 AM EDT - 13 days ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025, 8:45 AM EDT - 18 days ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 4:05 PM EDT - 19 days ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 28, 2025, 8:45 AM EDT - 5 weeks ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 10:23 AM EDT - 5 weeks ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Apr 8, 2025, 8:45 AM EDT - 7 weeks ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst

Mar 31, 2025, 3:03 PM EDT - 2 months ago

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 4:05 PM EDT - 2 months ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Feb 20, 2025, 8:45 AM EST - 3 months ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 28, 2025, 3:11 PM EST - 4 months ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 23, 2025, 8:10 AM EST - 4 months ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

SELLAS Announces Key Business Objectives for 2025

Jan 8, 2025, 8:20 AM EST - 5 months ago

SELLAS Announces Key Business Objectives for 2025

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 10, 2024, 8:30 AM EST - 6 months ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Dec 9, 2024, 8:45 AM EST - 6 months ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 27, 2024, 8:45 AM EST - 6 months ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:15 PM EST - 7 months ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 13, 2024, 8:00 AM EST - 7 months ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Nov 5, 2024, 9:55 AM EST - 7 months ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 15, 2024, 8:45 AM EDT - 8 months ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 4:05 PM EDT - 8 months ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 4:10 PM EDT - 10 months ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Aug 6, 2024, 8:45 AM EDT - 10 months ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 16, 2024, 9:05 AM EDT - 11 months ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 11 months ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 24, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 17, 2024, 9:05 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

Jun 10, 2024, 8:40 AM EDT - 1 year ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

May 1, 2024, 8:35 AM EDT - 1 year ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Apr 29, 2024, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout

Apr 19, 2024, 1:49 PM EDT - 1 year ago

Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 26, 2024, 7:35 AM EDT - 1 year ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Mar 19, 2024, 8:47 AM EDT - 1 year ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 15, 2024, 9:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Mar 8, 2024, 8:00 AM EST - 1 year ago

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

Mar 1, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

Feb 29, 2024, 8:00 AM EST - 1 year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

Feb 6, 2024, 8:30 AM EST - 1 year ago

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

Jan 25, 2024, 8:45 AM EST - 1 year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

Jan 9, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering

Jan 4, 2024, 9:01 AM EST - 1 year ago

SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering

SELLAS Life Sciences Announces Proposed Public Offering

Jan 3, 2024, 8:05 PM EST - 1 year ago

SELLAS Life Sciences Announces Proposed Public Offering

SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones

Jan 3, 2024, 7:30 AM EST - 1 year ago

SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Dec 27, 2023, 8:55 AM EST - 1 year ago

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Dec 21, 2023, 8:15 AM EST - 1 year ago

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia

Dec 14, 2023, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia

SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET

Dec 13, 2023, 8:30 AM EST - 1 year ago

SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET

SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia

Dec 4, 2023, 8:47 AM EST - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia